Hi @Vinneys,
This is an excerpt from the JPM website relevant to the conference held this year in Jan 23.
“Birthplace of Deals
The Conference is also the birthplace of a lot of deals, with companies announcing major transactions in the run-up.
Building off the momentum at the end of 2022, when J.P. Morgan's Global Head of Health Care Investment Banking, Mike Gaito, and his team led the industry’s biggest merger — the $28 billion sale of Horizon Therapeutics to Amgen — more than $3.5 billion worth of deals were announced to coincide with the Conference.
Chiesi’s $1.25 billion acquisition of rare disease drugmaker Amryt Pharma and AstraZeneca’s $1.3 billion buyout of CinCor Pharma, which gives it access hypertension and kidney disease treatments, were among the highlights.
These biotech buyouts gave the Conference a jumpstart, suggesting that the uptick in M&A activity that began in the second half of last year could stick around.
The M&A environment should “be really vibrant in 2023,” said Gaito, who opened the conference”
https://www.jpmorgan.com/solutions/cib/insights/healthcare-conference-highlights
I would anticipate that major pharmaceutical companies will already be researching the attendees (IHL) and their potential. A fantastic business to business marketing opportunity.
It has been a long time since Jul 19 when I first invested!
Hopefully exciting times coming.
- Forums
- ASX - By Stock
- IHL
- IHL - INCANNEX - HOLDERS RESEARCH
IHL - INCANNEX - HOLDERS RESEARCH, page-1199
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online